×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ONCY – oncolytics biotech inc. - common shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ONCY
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/3
03:31 pm
oncy
UPDATE -- The Efficiency Gap: Five Assets Where Price Has Yet To Reflect Reality
Low
Report
UPDATE -- The Efficiency Gap: Five Assets Where Price Has Yet To Reflect Reality
12/3
11:43 am
oncy
Oncolytics Biotech (ONCY) Loses 8.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner [Yahoo! Finance]
Low
Report
Oncolytics Biotech (ONCY) Loses 8.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner [Yahoo! Finance]
11/25
01:54 pm
oncy
Oncolytics Biotech (NASDAQ:ONCY) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Oncolytics Biotech (NASDAQ:ONCY) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
11/20
04:05 pm
oncy
Oncolytics Biotech® Provides Update on Special Meeting of Shareholders
Low
Report
Oncolytics Biotech® Provides Update on Special Meeting of Shareholders
11/19
07:04 pm
oncy
All You Need to Know About Oncolytics Biotech (ONCY) Rating Upgrade to Buy [Yahoo! Finance]
Medium
Report
All You Need to Know About Oncolytics Biotech (ONCY) Rating Upgrade to Buy [Yahoo! Finance]
11/19
09:55 am
oncy
Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer [Yahoo! Finance]
Neutral
Report
Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer [Yahoo! Finance]
11/19
09:45 am
oncy
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
Low
Report
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
11/19
09:00 am
oncy
Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer
High
Report
Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer
Date
Time
Symbol
Company Name
Action
%Chg
11/12/2025
05:28 pm
oncy
oncolytics biotech inc. - common shares
MISS
Report
-3.6%
oncolytics biotech inc. - common shares
8/8/2025
09:05 am
oncy
oncolytics biotech inc. - common shares
BEAT
Report
-7.7%
oncolytics biotech inc. - common shares
5/14/2025
04:01 pm
oncy
oncolytics biotech inc. - common shares
BEAT
Report
-3.4%
oncolytics biotech inc. - common shares
3/7/2025
07:00 am
oncy
oncolytics biotech inc. - common shares
MISS
Report
-10.5%
oncolytics biotech inc. - common shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/20
04:07 pm
oncy
Form 6-K ONCOLYTICS BIOTECH INC For: Nov 20
Low
Report
Form 6-K ONCOLYTICS BIOTECH INC For: Nov 20
11/19
09:03 am
oncy
Form 6-K ONCOLYTICS BIOTECH INC For: Nov 19
Medium
Report
Form 6-K ONCOLYTICS BIOTECH INC For: Nov 19
11/14
03:05 pm
oncy
Form SCHEDULE 13G/A ONCOLYTICS BIOTECH INC Filed by: Anson Funds Management LP
Low
Report
Form SCHEDULE 13G/A ONCOLYTICS BIOTECH INC Filed by: Anson Funds Management LP
11/12
05:29 pm
oncy
Form 6-K ONCOLYTICS BIOTECH INC For: Sep 30
Medium
Report
Form 6-K ONCOLYTICS BIOTECH INC For: Sep 30
11/4
08:11 am
oncy
Form 6-K ONCOLYTICS BIOTECH INC For: Nov 04
High
Report
Form 6-K ONCOLYTICS BIOTECH INC For: Nov 04
10/28
07:43 am
oncy
Form 6-K ONCOLYTICS BIOTECH INC For: Oct 28
Low
Report
Form 6-K ONCOLYTICS BIOTECH INC For: Oct 28
10/20
09:02 am
oncy
Form 6-K ONCOLYTICS BIOTECH INC For: Oct 20
Low
Report
Form 6-K ONCOLYTICS BIOTECH INC For: Oct 20
10/20
06:02 am
oncy
Form 6-K ONCOLYTICS BIOTECH INC For: Oct 17
Low
Report
Form 6-K ONCOLYTICS BIOTECH INC For: Oct 17
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/24
Oncolytics Biotech® Announces Favourable AWARE-1 Safety Update
33.3%
1/3 Form SUPPL ONCOLYTICS BIOTECH INC 17.3%
10/30 Breast Cancer Awareness Month Arrives With New Teamwork From Biotech Developers on the Way 17.2%
8/16 Form SUPPL ONCOLYTICS BIOTECH INC 15.6%
11/19 Oncolytics Biotech, Inc. (NASDAQ: ONCY) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 14.5%
1/2 Oncolytics Biotech, Inc. (NASDAQ: ONCY) had its price target raised by analysts at Roth Capital from $6.80 to $9.00. They now have a "buy" rating on the stock. 13.8%
10/15 Oncolytics Biotech(R) Presents Clinical Data Highlighting the Effectiveness of Intravenous Delivery to and Replication of Pelareorep in Tumors 10.6%
3/19 Oncolytics Biotech, Inc. (NASDAQ: ONCY) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. They now have a $300.00 price target on the stock. 10.0%
3/4 Oncolytics Biotech, Inc. (NASDAQ: ONCY) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. 8.7%
11/12 Form 6-K ONCOLYTICS BIOTECH INC For: Nov 12 8.1%
1/3 Form SUPPL ONCOLYTICS BIOTECH INC 17.3%
10/30 Breast Cancer Awareness Month Arrives With New Teamwork From Biotech Developers on the Way 17.2%
8/16 Form SUPPL ONCOLYTICS BIOTECH INC 15.6%
11/19 Oncolytics Biotech, Inc. (NASDAQ: ONCY) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 14.5%
1/2 Oncolytics Biotech, Inc. (NASDAQ: ONCY) had its price target raised by analysts at Roth Capital from $6.80 to $9.00. They now have a "buy" rating on the stock. 13.8%
10/15 Oncolytics Biotech(R) Presents Clinical Data Highlighting the Effectiveness of Intravenous Delivery to and Replication of Pelareorep in Tumors 10.6%
3/19 Oncolytics Biotech, Inc. (NASDAQ: ONCY) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. They now have a $300.00 price target on the stock. 10.0%
3/4 Oncolytics Biotech, Inc. (NASDAQ: ONCY) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. 8.7%
11/12 Form 6-K ONCOLYTICS BIOTECH INC For: Nov 12 8.1%
TOP News Decliners
8/13
Oncolytics Biotech(R) Announces Public Offering of Common Shares and Warrants
-34.0%
11/5 Oncolytics Biotech(R) to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights -21.9%
1/14 Form 6-K ONCOLYTICS BIOTECH INC For: Jan 13 -20.5%
1/1 Oncolytics Biotech, Inc. (NASDAQ: ONCY) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -18.4%
3/5 Oncolytics Biotech® Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights -17.3%
1/13 Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting Pelareorep's Unique Ability to Activate the Immune System in Late Stage Multiple Myeloma -16.0%
6/5 Oncolytics Biotech's (ONCY) Co-Development Agreement with Pfizer and Merck KGaA Call (Transcript) [Seeking Alpha] -14.1%
12/6 Oncolytics Biotech(R) Regains Compliance with Nasdaq Minimum Bid Price Requirement -12.3%
3/9 Form SUPPL ONCOLYTICS BIOTECH INC -11.1%
6/5 Oncolytics Biotech (R) Announces Study to Investigate Combination of Pelareorep and Avelumab in Metastatic Breast Cancer in Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer -10.0%
11/5 Oncolytics Biotech(R) to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights -21.9%
1/14 Form 6-K ONCOLYTICS BIOTECH INC For: Jan 13 -20.5%
1/1 Oncolytics Biotech, Inc. (NASDAQ: ONCY) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -18.4%
3/5 Oncolytics Biotech® Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights -17.3%
1/13 Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting Pelareorep's Unique Ability to Activate the Immune System in Late Stage Multiple Myeloma -16.0%
6/5 Oncolytics Biotech's (ONCY) Co-Development Agreement with Pfizer and Merck KGaA Call (Transcript) [Seeking Alpha] -14.1%
12/6 Oncolytics Biotech(R) Regains Compliance with Nasdaq Minimum Bid Price Requirement -12.3%
3/9 Form SUPPL ONCOLYTICS BIOTECH INC -11.1%
6/5 Oncolytics Biotech (R) Announces Study to Investigate Combination of Pelareorep and Avelumab in Metastatic Breast Cancer in Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer -10.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: